174 related articles for article (PubMed ID: 25190017)
1. Meta-analysis of studies on the association between the NF-κB1-94ins/del ATTG promoter polymorphism and cancer.
Nian X; Zhang W; Li L; Sun Y; Sun E; Han R
Tumour Biol; 2014 Dec; 35(12):11921-31. PubMed ID: 25190017
[TBL] [Abstract][Full Text] [Related]
2. Association of NFKB1 -94ins/delATTG promoter polymorphism with susceptibility to autoimmune and inflammatory diseases: a meta-analysis.
Zou YF; Wang F; Feng XL; Tao JH; Zhu JM; Pan FM; Su H
Tissue Antigens; 2011 Jan; 77(1):9-17. PubMed ID: 21155719
[TBL] [Abstract][Full Text] [Related]
3. Risk association between the NF-κB1 -94ins/delATTG promoter polymorphism and inflammatory bowel diseases: a meta-analysis.
Liang M; Xu X; Gong Y; Tang Y; Lin L
Dig Dis Sci; 2012 Sep; 57(9):2304-9. PubMed ID: 22828805
[TBL] [Abstract][Full Text] [Related]
4. An updated meta-analysis of 37 case-control studies on the association between NFKB1 -94ins/del ATTG promoter polymorphism and cancer susceptibility.
Luo YQ; Wang D; Gong T; Zhu J
Oncotarget; 2016 Sep; 7(36):58659-58670. PubMed ID: 27463002
[TBL] [Abstract][Full Text] [Related]
5. NFKB1 -94insertion/deletion ATTG polymorphism and cancer risk: Evidence from 50 case-control studies.
Fu W; Zhuo ZJ; Chen YC; Zhu J; Zhao Z; Jia W; Hu JH; Fu K; Zhu SB; He J; Liu GC
Oncotarget; 2017 Feb; 8(6):9806-9822. PubMed ID: 28039461
[TBL] [Abstract][Full Text] [Related]
6. Relationship between the
Chen J; Ge D; Xiong Y
Clin Exp Hypertens; 2019; 41(6):577-582. PubMed ID: 30285510
[No Abstract] [Full Text] [Related]
7. The functional 4-bp insertion/deletion ATTG polymorphism in the promoter region of NF-KB1 reduces the risk of BC.
Eskandari-Nasab E; Hashemi M; Ebrahimi M; Amininia S
Cancer Biomark; 2016; 16(1):109-15. PubMed ID: 26835711
[TBL] [Abstract][Full Text] [Related]
8. Contributions of NFKB1 -94insertion/deletion ATTG polymorphism to the susceptibility of gastrointestinal cancers: A meta-analysis.
Wu H; Liang J
J Cell Mol Med; 2021 Nov; 25(22):10674-10683. PubMed ID: 34672421
[TBL] [Abstract][Full Text] [Related]
9. Association Between the NFKB1-94ins/del ATTG Polymorphism (rs28362491) and Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Chen QJ; Lai HM; Zhao L; Ma YT; Li XM; Zhai H; Zhou Y; He CH; Chen BD; Liu F; Yang YN
Genet Test Mol Biomarkers; 2016 Mar; 20(3):105-11. PubMed ID: 26799199
[TBL] [Abstract][Full Text] [Related]
10. NF-
Yu J; Hua M; Zhao X; Wang R; Zhong C; Zhang C; Wang R; Li G; He N; Hou M; Ma D
J Immunol Res; 2018; 2018():8170436. PubMed ID: 30140708
[TBL] [Abstract][Full Text] [Related]
11. Association between NFKB1 -94ins/delATTG promoter polymorphism and cancer risk: a meta-analysis.
Zou YF; Yuan FL; Feng XL; Tao JH; Ding N; Pan FM; Wang F
Cancer Invest; 2011 Jan; 29(1):78-85. PubMed ID: 21166501
[TBL] [Abstract][Full Text] [Related]
12. Association between the NFKB1-94ins/del ATTG polymorphism and cancer risk: an updated meta-analysis.
Duan W; Wang E; Zhang F; Wang T; You X; Qiao B
Cancer Invest; 2014 Aug; 32(7):311-20. PubMed ID: 24827594
[TBL] [Abstract][Full Text] [Related]
13. Investigation of NF-κB1 and NF-κBIA gene polymorphism in non-small cell lung cancer.
Oltulu YM; Coskunpinar E; Ozkan G; Aynaci E; Yildiz P; Isbir T; Yaylim I
Biomed Res Int; 2014; 2014():530381. PubMed ID: 24707489
[TBL] [Abstract][Full Text] [Related]
14. NFKB1 promoter -94 insertion/deletion ATTG polymorphism (rs28362491) is associated with severity and disease progression of rheumatoid arthritis through interleukin-6 levels modulation in Egyptian patients.
Elkhawaga SY; Gomaa MH; Elsayed MM; Ebeed AA
Clin Rheumatol; 2021 Jul; 40(7):2927-2937. PubMed ID: 33459954
[TBL] [Abstract][Full Text] [Related]
15. Updated meta-analysis of NFkappaB1 -94ins/Delattg promoter polymorphism and cancer risk based on 19 case-control studies.
Wang X; Lu P; Xu L; Xu Y; Shi Z; Xu J; Wang Y; Zhang J; Wang X; Cao L; Liu N; Yin Y; You Y
Asian Pac J Cancer Prev; 2011; 12(10):2479-84. PubMed ID: 22320942
[TBL] [Abstract][Full Text] [Related]
16. Association between NFKB1 -94ins/del ATTG Promoter Polymorphism and Cancer Susceptibility: An Updated Meta-Analysis.
Yang X; Li P; Tao J; Qin C; Cao Q; Gu J; Deng X; Wang J; Liu X; Wang Z; Wu B; Gu M; Lu Q; Yin C
Int J Genomics; 2014; 2014():612972. PubMed ID: 24895544
[TBL] [Abstract][Full Text] [Related]
17. Genetic association between NFKB1 -94 ins/del ATTG Promoter Polymorphism and cancer risk: a meta-analysis of 42 case-control studies.
Wang D; Xie T; Xu J; Wang H; Zeng W; Rao S; Zhou K; Pei F; Zhou Z
Sci Rep; 2016 Jul; 6():30220. PubMed ID: 27443693
[TBL] [Abstract][Full Text] [Related]
18. Association of NFKB1 -94ins/del ATTG promoter polymorphism with susceptibility to and phenotype of Graves' disease.
Kurylowicz A; Hiromatsu Y; Jurecka-Lubieniecka B; Kula D; Kowalska M; Ichimura M; Koga H; Kaku H; Bar-Andziak E; Nauman J; Jarzab B; Ploski R; Bednarczuk T
Genes Immun; 2007 Oct; 8(7):532-8. PubMed ID: 17690684
[TBL] [Abstract][Full Text] [Related]
19. The functional role of nuclear factor kappa-kappaB1 -94 ins/del ATTG promotor gene polymorphism in Behçet's disease: an exploratory study.
Yalcin B; Atakan N; Alli N
Clin Exp Dermatol; 2008 Aug; 33(5):629-33. PubMed ID: 18616724
[TBL] [Abstract][Full Text] [Related]
20. NFKB1 -94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors.
Burnik FS; Yalçin S
Chemotherapy; 2009; 55(5):381-5. PubMed ID: 19752553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
